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Background Vietnam is in the process of an epidemiological transition, with cardiovascular
disease (CVD) now ranked as the leading cause of death. The burden of CVD
will continue to rise unless effective interventions for addressing its underlying
risk factors are put in place.
Objectives To assess the costs, health effects and cost-effectiveness of a set of personal and
non-personal prevention strategies to reduce CVD in Vietnam, including mass
media campaigns for reducing consumption of salt and tobacco, drugs for
lowering blood pressure or cholesterol, and combined pharmacotherapy for
people at varying levels of absolute risk of a cardiovascular event.
Methods WHO-CHOICE methods and analytical models were employed, using local data
to estimate the costs, effects and cost-effectiveness of 12 population and
individual interventions implemented singly or in combination. Costs were
measured in Vietnamese Dong for the year 2007 (discounted at a rate of 3% per
year), while health effects were expressed in age-weighted and discounted
disability-adjusted life years (DALYs) averted.
Results A health education programme to reduce salt intake (VND 1 945 002 or US$118
per DALY averted) and individual treatment of systolic blood pressure above
160 mmHg (VND 1 281 596 or US$78 per DALY averted) were found to be the
most cost-effective measures for population- and individual-based approaches,
respectively. Where budget is very limited, a mass media education programme
on salt intake and a combination mass media programme addressing salt intake,
cholesterol and tobacco should be selected first. If more resources become
available, greatest population health gains can be achieved via individual
treatment of systolic blood pressure and the absolute risk approach to CVD
prevention.
Conclusions Contextualization of WHO-CHOICE using local data provides health
decision-makers with more sound economic evidence for policy debates on
prioritizing health interventions to reduce cardiovascular diseases in Vietnam.
When used, cost-effectiveness analysis could increase efficiency in allocating
scare resources.
Keywords Cost-effectiveness, cardiovascular disease, systolic blood pressure, cholesterol,
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KEY MESSAGES
 The most efficient preventive interventions to reduce risk factors for cardiovascular disease in Vietnam are highly
cost-effective (each healthy year of life gained costs less than average annual income per capita).
 With no budget constraint, the single most cost-effective preventive strategy is individual treatment of systolic blood
pressure over 160 mmHg, followed by combination drug therapy for individuals with an elevated risk of experiencing a
CVD event over the next 10 years. If resources are highly restricted, population-based mass media strategies aimed at
reducing levels of cholesterol and dietary salt intake become the most probable interventions to implement.
 Using local and context-specific information to apply generalized cost-effectiveness methods at the national level offers a
promising approach to improved evidence-based health policy-making in developing countries.
Introduction
Background
Cardiovascular disease (CVD) is the leading cause of morbidity
and mortality worldwide, with 80% of total deaths occurring in
developing countries (WHO 2002). The most common causes of
CVD morbidity and mortality are ischemic heart disease (IHD),
stroke and congestive heart failure (CHF). Risk factors include,
amongst other things, tobacco use, high blood pressure, high
cholesterol level, high body mass index and alcohol consump-
tion. Among these risk factors, smoking, high systolic blood
pressure and cholesterol concentration account for more than
70% of the burden of CVD (Ezzati 2004).
Vietnam has been undergoing an epidemiological transition,
in which the overall morbidity and mortality pattern has shifted
from communicable diseases to non-communicable diseases.
Increased non-communicable diseases leave the country with a
double financial burden, resulting from an established high
burden of infectious diseases and at the same time the
escalating morbidity and mortality of non-communicable
diseases such as diabetes, cancer and especially CVD. In
addition, Vietnam has a very high injury burden, mainly as a
result of road traffic injuries, prompting the concept of the
triple burden of disease. A recent national burden of disease
study conducted in 2008 (T Vos, personal communication,
2009) found that cardiovascular diseases, mainly strokes and
IHD, account for one-third of total deaths, and are ranked first
among the top 10 leading causes of mortality. Moreover, these
diseases were found to make up the largest share (approxi-
mately 20%) of the total burden of disability-adjusted life years
(DALYs) lost.
Evidence has shown that key risk factors for CVD in Vietnam
are either on the rise or already at alarming levels. First, the
Vietnam National Health Survey (VNHS) 2001/02 estimated
that the prevalence of hypertension was 16.9% among people
aged 25–65 years (MOH 2003), a 51% increase compared with
1992. By 65 years of age around half of all men and women
suffer from hypertension. Secondly, analyses using Vietnam
Living Standards Survey 1992/93 and VNHS 2002/03 showed an
increased trend for the prevalence of overweight and obesity
(Tuan et al. 2008). In addition to this, a recently conducted
study (Cuong et al. 2007) found that the prevalence of
overweight and obesity in adults is 6.4% in Ho Chi Minh
City, signalling an emerging public health problem in urban
areas. Thirdly, cooking culture and habitual eating preferences
for using salt predominantly in preserving meat and fish, and
in seasoning and sauces used during cooking and at the table,
make the salt intake level of the Vietnamese higher than the
level recommended by the World Health Organization (WHO)
of 5 grams per day (WHO 2003). Fourthly, awareness
around CVD risk factors among the Vietnamese is relatively
low (approximately 50%), but considerably lower than this
in rural areas (Khai et al. 2008). Finally, a smoking preva-
lence of 56% among Vietnamese males aged over 16 years
places them among the heaviest smokers in the world
(MOH 2003).
Evidently, the burden of cardiovascular diseases will continue
to increase in Vietnam unless effective strategies for addressing
risk factors are in place. While further increases in both internal
and external financing for CVD control and prevention pro-
grammes are needed, it is extremely important for the current
resources to be used efficiently. A recognized tool for guiding
resource allocation is cost-effectiveness analysis. A decade ago,
the WHO introduced WHO-CHOICE (CHOosing Interventions
that are Cost Effective) with the intention of assisting resource
allocation in the health sector, both at the global and national
levels (Murray et al. 2000). Key aspects of the WHO-CHOICE
approach to cost-effectiveness analysis are described in detail
elsewhere (Adam et al. 2003; Edejer et al. 2003; Hutubessy et al.
2003; Lauer et al. 2003). Regional information on costs and
population health effectiveness of these diseases has been made
available on the WHO website (http://www.who.int/choice/en/),
as are further details on the WHO-CHOICE approach and
methodology.
Study objective
By applying WHO-CHOICE models and using locally available
data, the overall objective of this study is to inform policy
makers about the costs, effects and cost-effectiveness of
preventive interventions, and how they can be combined
efficiently to prevent and reduce CVD risk factors in Vietnam.
Such application of WHO-CHOICE models for cost-effectiveness
analysis of interventions to reduce CVD in Vietnam is promising
and realistic for a couple of reasons. First, the ingredient
approach developed by WHO-CHOICE allows country analysts
to adapt regional-level information down to the national level.
Second, several surveys such as risk factors of non-
communicable diseases and burden of disease, which have
been recently carried out in Vietnam, provide valuable national
demographic and epidemiological parameters for modelling
population effectiveness. With respect to health policy, the
contextualization of WHO-CHOICE will enable the Ministry of
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Health to know whether or not the resources currently devoted
to cardiovascular prevention programmes achieve as much
health effectiveness as they could; and how best to use
additional resources if they become available.
Methods and data
Overview of WHO-CHOICE contextualization process
Figure 1 provides a methodological framework within which
WHO-CHOICE estimates and models can be translated to the
context of Vietnam. There are four key phases for the
contextualization. In the first phase, we formed a panel of
experts including Vietnamese experts in health economics,
epidemiology, public health, and health communication and
education. Based on their expertise and knowledge of
Vietnam’s health situation, the experts advised us on the
selection of interventions and, more importantly, helped to
re-adjust the prices and quantities provided by WHO-CHOICE,
as well as the current coverage of interventions. The second and
third phases involved data collection and subsequent modelling
of intervention effectiveness and costs at the population level,
as described in detail below. The final phase concerns the
assimilation of costs and effects data into estimates of inter-
vention cost-effectiveness, including assessment of the extent to
which baseline findings are sensitive to plausible changes to
key input parameters.
Description of interventions and their effects
Preventive interventions for CVD fall into two categories:
population-wide and personal interventions, targeting the
general population and individuals who are at high risk,
respectively. The former is based on the concept that the
majority of cases of CVD occur among persons with medium
and low levels of risk (Rose et al. 2008). Achieving a small
change in risk factors in the population at large may bring
greater benefits than a large change in a sub-population of
high-risk cases (Kottke et al. 1988).
Individual interventions were selected based on published
studies (Murray et al. 2003; Gaziano et al. 2006), and experts’
opinion (see Table 1). Population-wide interventions are
comprised of three separate health education programmes
aimed at reducing salt intake, cholesterol levels and tobacco
consumption through mass media, together with a combined
mass media strategy (for which we assumed an additive effect
due to the fact that each of the individual campaigns target a
specific and distinct risk factor). Health education messages are
modelled to be broadcasted on television and radio channels at
both central and provincial levels, as well as communicated in
print via newspapers, wall posters and fliers/leaflets. In the
particular case of the salt reduction strategy, we also include a
voluntary agreement among manufacturers of processed foods
to reduce salt content levels.
Individual interventions are divided into two sub-groups:
individual treatment based on elevated levels of systolic blood
pressure and cholesterol, and individual treatment based on the
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Figure 1 Methodological framework of WHO-CHOICE analysis
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absolute risk of a cardiovascular event in the next 10 years.
Individual treatment to reduce systolic blood pressure com-
prises a regime of 50 mg per day atenolol and 25 mg per day
hydrochlorothiazide for those who have elevated levels of
systolic blood pressure of 140 mmHg (I1) or >160 mmHg (I2).
Cholesterol-lowering drug treatment including 40 mg per day
simvastatin is offered for those who have elevated cholesterol
for two thresholds of cholesterol concentration >5.7 (I3) and
mmol/l >6.2 mmol/l (I4). Individual treatment based on the
absolute risk of a cardiovascular event over 10 years was
assessed at four separate levels (5%, 15%, 25% and 35%; I5–I8),
which has typically consisted of a regime of aspirin, diuretic,
b-blocker and statin (Williams 2006). However, the choice of
first-line drugs remains the subject of debate, especially
concerning antihypertensive drugs in those without existing
CVD (Antithrombotic Trialists Collaboration 2002; Dahlof et al.
2005). The regime proposed for this analysis is based on the
traditionally proposed regime of 100 mg per day aspirin, 25 mg
per day hydrochlorothiazide, 50 mg per day atenolol and 40 mg
per day simvastatin.
Effectiveness estimates, expressed in terms of percentage
improvements to the outcome of interest (such as total
cholesterol level or daily salt intake), were taken from system-
atic reviews of randomized trials, meta-analyses and published
articles on cost-effectiveness analysis (Table 1). For all individ-
ual interventions, and as advised by the panel of experts, a
compliance rate of 50% was applied.
Modelling the impact of CVD preventive measures
on disease outcomes
Estimation of the impact of CVD preventive strategies on final
disease outcomes is quite complex, since there is a causal chain
of effects that needs to be accounted for (or put another way,
available evidence of intervention effect does not directly relate
to a disease endpoint such as the incidence of stroke, but rather
to underlying risk factors that are known to increase the
probability of having a stroke). Accordingly, analysis comprised
a number of steps. First, modelling was employed to estimate
expected rates of disease incidence (specifically, IHD and
stroke) that would occur in the population with and without
the implementation of the prevention measures. This step was
undertaken by means of a simulation model—based on the
Asia Pacific Cohort Studies Collaboration—that applies the
aforementioned effect sizes to the observed risk factor profile of
different age and sex groups in the Vietnamese population
(Table 2). Stata 10 (Stata Corporation, Texas, USA) was
employed using a syntax specifically developed by WHO-
CHOICE for this process.
Second, PopMod (version 4.5), one of the WHO-CHOICE
tools, was used to estimate the lifetime health gains experi-
enced by the Vietnamese population as a result of these
intervention-induced changes in disease incidence. It has been
described in detail by Lauer et al. (2003). PopMod tracks what
would happen to each age and sex cohort in the Vietnamese
population over a lifetime period (taken to be 100 years), first
without any CVD prevention measures in place and then with
the various interventions in place for the initial 10 years only
(after which incidence rates go back to their ’non-intervention’T
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levels). Thus, the difference in healthy years lived (which is
equivalent to the number of disability-adjusted life years or
DALYs incurred) by the population with versus without
intervention provides our estimate of population-level interven-
tion effect. DALYs in the base case analysis were age-weighted
and discounted at an annual rate of 3%.
For the current epidemiology of IHD and stroke, including
estimates of the average level of disability associated with these
health conditions (on a 0–1 scale, where 0 denotes no
disability), we used data from the national burden of disease
study in Vietnam (T Vos, personal communication, 2009).
Prevalence information of systolic blood pressure and smoking
was collected from the 2001 and 2008 risk factor surveys (Khai
et al. 2008) and Vietnam National Health Survey 2001/02 (MOH
2003), respectively, while the relative risks for IHD and stroke
per unit increase in each risk factor were based on the
estimates of WHO’s Comparative Risk Assessment Project for
the Western Pacific Region B (Ezzati 2004). Baseline salt intake
profile was drawn from the InterSalt study (Intersalt 1988) (see
Table 2). Data on demography and mortality rates by gender
and age group were taken from the United Nations Population
Division’s Bureau for the year 2007.
Intervention costs
Costs are comprised of programme and patient-related costs.
Programme costs are those incurred at the national, provincial
and district administrative levels above the health facility level
itself (such as training, programme administration and mass
media), while patient costs are costs at the point of delivery
consisting of diagnostic and laboratory tests, consultation,
drugs, and hospital and health centre visits. Total costs were
obtained by multiplying quantities by prices. To estimate the
costs, the entire set of ingredients and their quantities
developed by WHO-CHOICE for interventions to reduce CVD
were re-evaluated by the local panel of experts, making them
more appropriate to the context of Vietnam.
In terms of resource quantities, and in addition to the drug
regimens described above, all individual preventive strategies
require laboratory tests (measuring blood pressure, cholesterol
concentration and blood sugar), four health care provider visits
per year, and 1.5 outpatient visits per year for health education.
Population-based strategies, by contrast, use up programme
management staffing inputs and mass media resources (for
example, six weekly TV and radio emissions at the national
level and two weekly emissions in each province were modelled
for the salt and tobacco campaigns).
Prices/unit costs of the ingredients were collected from a
variety of sources. Concretely, prices of drugs were derived
from the International Drug Price database published by
Management Sciences for Health (MSH) in 2007 (Table 3)
(MSH 2007). These prices were added with a mark-up of 30%
for transportation and distribution, as estimated by Hutton and
Baltussen (2005). Personnel payment norms were based on
salary scales used by the European Union and United Nations
agencies in Vietnam (UN-EU 2007) and the Government
regulation (Government of Vietnam 2004). Prices of media
and other IEC material were taken directly from Vietnam
Television, Voice of Vietnam, local television and radio stations,
and Thanh Nien publishing. Unit costs for inpatient and
outpatient care were based on a Vietnamese costing study
conducted at central, provincial and district levels (Flessa and
Dung 2004).
A costing template (CostIt) developed by WHO-CHOICE was
employed to aggregate cost components over the intervention
Table 2 Epidemiology of cardiovascular disease (CVD) and risk factors in Vietnam
Gender/age (years)
Disease
incidence
Systolic blood
pressure (mmHg)
Total blood
cholesterol (mmol/L)
Smoking
(prevalence)
Daily
salt
intake
IHD
(per 1000)
Stroke
(per 1000) Mean S.D.
Relative
risk for
IHD
Relative
risk for
stroke Mean S.D.
Relative
risk for
IHD
Relative
risk for
stroke Mean
Relative
risk for
CVD
NaCl
per day
Male
30–44 0.3 0.1 117.1 14.9 1.07 1.09 4.5 1.1 3.65 1.48 0.72 2.43 11.2
45–59 1.0 0.5 125.9 20.7 1.05 1.07 4.6 1.1 2.08 1.35 0.68 2.43 10.8
60–69 2.1 1.9 133.2 25.5 1.03 1.05 4.7 1.2 1.55 1.25 0.58 1.84 10.8
70–79 2.3 2.1 136.1 27.5 1.02 1.03 4.8 1.1 1.42 1.17 0.47 1.7 10.8
80þ 4.4 3.5 136.1 27.5 1.01 1.02 4.8 1.1 1.42 1.09 0.3 1.38 10.8
Female
30–44 0.5 0.3 110.6 14.6 1.07 1.09 4.3 1 3.65 1.48 0.01 2.43 10.1
45–59 4.5 3.0 122.4 20.3 1.05 1.07 4.8 1.1 2.08 1.35 0.03 2.43 9.7
60–69 20.0 12.3 132.3 25 1.03 1.05 5.1 1.3 1.55 1.25 0.05 1.84 9.7
70–79 40.9 32.6 136.2 26.9 1.02 1.03 5.1 1.2 1.42 1.17 0.04 1.7 9.7
80þ 57.6 53.2 136.2 26.9 1.01 1.02 5.1 1.2 1.42 1.09 0.02 1.38 9.7
Note: IHD¼ ischemic heart disease.
Data sources: Disease incidence: Viet Nam burden of disease study (T Vos, personal communication, 2009); Blood pressure: Viet Nam Risk Factor Surveys (Khai
et al. 2008); Smoking: Vietnam National Health Survey (MOH 2003); Blood cholesterol and all relative risk estimates: The Comparative Risk Assessment Project
(Ezzati 2004); Salt intake: InterSalt study (Intersalt 1998).
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implementation horizon (10 years). All costs beyond the base
year were discounted at a rate of 3% per year, consistent
with other guidelines (Gold et al. 1996; Drummond 2005).
Capital and start-up costs were likewise annualized over the
assumed life-time of the intervention. Moreover, to adjust for
capacity utilization, we assumed a norm of 80% for capacity
utilization as recommended by WHO-CHOICE. Throughout this
paper, all costs were estimated using societal perspective and
Vietnamese Dong (VND) with an exchange rate of US$1¼VND
16 421 for the base year 2007.
Calculating cost-effectiveness
When calculating cost-effectiveness ratios, we considered
what would happen from today if all resources could be
re-allocated. Put another way, the cost-effectiveness of each
interventions was assessed in relation to the null or coun-
terfactual scenario, in which none of the proposed
interventions was implemented; this is the average cost-
effectiveness ratio. In addition, we calculated incremental
cost-effectiveness ratios for (non-dominated) interventions
that fall on the efficiency frontier or cost-effectiveness
Table 3 Unit costs for health intervention resource inputs
Domain Measure Vietnamese Dong US$
Secondary care District hospital 11 330 0.69
Provincial hospital 14 902 0.91
Primary care 10 minutes per visit 19 186 1.17
20 minutes per visit 22 880 1.39
Drugs
Aspirin 100 mg dose 36 0.002
Atenolol 50 mg dose 138 0.008
Hydrochlorothiazide 25 mg dose 49 0.003
Simvastatin 40 mg dose 657 0.04
Diagnostic tests
Renal function 6904 0.42
Serum lipids 8918 0.543
Blood glucose 3596 0.219
Total cholesterol 4890 0.298
Hepatic function 13 233 0.806
Salaries (gross per year)
Nurses 39 503 128 2406
Health worker 22 981 595 1400
Medical specialist 91 895 543 5596
Medical officer 63 744 761 3882
Programme director 91 895 543 5596
Programme manager 63 744 761 3882
Administration officer 39 503 128 2406
Secretary/receptionist 22 981 595 1400
Media (national level)
Television time 1 minute 21 067 271 1282.95
Radio time 1 minute 2 532 665 154.23
Newspapers 1/4 page advertisement 17 585 554 1070.92
Wall posters 1 square metre 6589 0.40
Flyers/leaflets A4 size 1387 0.08
Media (provincial level)
Television time 1 minute 3 805 795 231.77
Radio time 1 minute 457 525 27.86
Newspapers 1/4 page advertisement 3 176 824 193.47
Wall posters 1 square metre 6589 0.40
Flyers/leaflets A4 size 1387 0.08
Per diems (national level) 395 042 24
Sources: Drug prices: MSH (2007); inpatient and outpatient care: Flessa and Dung (2004); salaries: UN-EU (2007) and Government of Vietnam (2004);
media and other IEC material prices: from Vietnam Television, Voice of Vietnam, local television and radio stations, and Thanh Nien publishing.
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expansion path (see Figure 2 for a graphical demonstration of
this concept).
Classification of cost-effective interventions was based on the
suggestions from the Commission on Macroeconomics and
Health (CMH) (WHO 2001), in which to be considered
cost-effective, an intervention has to have a cost-effectiveness
ratio of less than three times gross domestic product (GDP)
per capita. Below that threshold, WHO-CHOICE considers an
intervention to be very cost-effective if each DALY can
be averted at a cost of less than GDP per capita (which in
the Vietnamese context was VND 13 456 000 or US$820 in
2007). Since this is a country-specific economic analysis, we
report results using local currency units, but make regular
conversions to US dollars to help those unfamiliar with
Vietnamese Dong.
Uncertainty analysis
We assessed sensitivity analyses on the health effects of various
interventions using the lower and upper limits (Table 1) and
also the effect of changes in prices (from a half to double the
base estimates). We also recalculated the cost-effectiveness
ratios without age weight and discounting. Best-case and
worst-case scenario analyses were undertaken using lower
health effect limits and highest drug prices (worst-case), and
upper health effect limits and lowest drug prices (best-case).
Finally, we did a probabilistic, multivariate sensitivity analysis
using Monte Carlo League (MCLeague) software (another of
the WHO-CHOICE tools), assuming a coefficient of variation of
15% on the cost side and 25% on the effectiveness side with
1000 randomly selected sets of variables.
Results
Table 4 represents total annual costs and health effectiveness in
terms of age-weighted and discounted DALYs averted, the
average cost-effectiveness ratio, incremental cost-effectiveness
ratio, and the cost-effectiveness category for all 23 interven-
tions. The least costly interventions are health education
programmes through mass media, with a total cost per year
of VND 89 billion (US$0.06 per capita). By contrast, combin-
ation drug treatment for individuals with a 5% absolute risk of
a cardiovascular event is the most costly intervention (VND
4121 billion/year, equivalent to US$2.9 per capita). In terms of
effectiveness, individual interventions save more DALYs than
population-wide interventions, but are more costly. Specifically,
population interventions can avert 7000–75 000 DALYs per year
when implemented singly or in combination, while individual
interventions can save 50 000–400 000 DALYs annually.
According to the Commission on Macroeconomics and
Health’s classification, all interventions are cost-effective, i.e.
below the threshold of three times GDP per capita.
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Figure 2 Expansion path for cardiovascular disease interventions.
Note: DALY¼ disability-adjusted life year.
Table 4 Annual cost, effects and cost-effectiveness of interventions
Intervention
Costs per year
(VND, billions)
DALYs averted
per year
ACER
(VND per DALY saved)
ICER
(VND per DALY saved)
CMH
category*
Media salt campaign 89 45 939 1 945 002 Dominated Very cost-effective
Media smoking campaign 89 7250 12 324 059 Dominated Very cost-effective
Media cholesterol campaign 89 36 982 2 416 075 Dominated Very cost-effective
Mass media combination 167 75 379 2 211 140 Dominated Very cost-effective
Treatment of SBP >140 mmHg 941 256 559 3 660 315 13 194 115 Very cost-effective
Treatment of SBP >160 mmHg 264 205 329 1 281 596 1 281 596 Very cost-effective
Treatment of cholesterol >5.7 mmol/l 2460 78 179 31 469 764 Dominated Cost-effective
Treatment of cholesterol >6.2 mmol/l 1174 52 392 22 404 550 Dominated Cost-effective
Combination treatment (>5% risk) 4121 404 684 10 157 911 30 240 689 Very cost-effective
Combination treatment (>15% risk) 2308 344 868 6 674 633 17 547 288 Very cost-effective
Combination treatment (>25% risk) 1584 303 714 5 201 348 13 585 810 Very cost-effective
Combination treatment (>35% risk) 1129 264 716 4 251 785 Dominated Very cost-effective
Notes: ACER¼ average cost-effectiveness ratio; ICER¼ incremental cost-effectiveness ratio; DALY¼disability-adjusted life year; CMH¼Commission on
Macroeconomics & Health; SBP¼ systolic blood pressure.
*Very cost-effective: <GDP per capita; Cost-effective: <3 times GDP per capita; Not cost-effective: >3 times GDP per capita.
GDP per capita in Vietnam for the year 2007 was VND 13 465 000 (US$820).
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Furthermore, all population interventions implemented either
in isolation or in combination are very cost-effective (below the
threshold of GDP per capita). Among the population interven-
tions, the health education programme to reduce salt intake is
the most cost-effective (VND 1 945 002 or US$118 per DALY
averted), followed by the mass media combination programme
(VND 2 211 140 or US$135 per DALY averted). For individual
interventions, results show that both treatment interventions
based on elevated levels that aim to reduce cholesterol are less
cost-effective when compared with all other measures.
Individual treatment for cholesterol >5.7 mmol is least
cost-effective (VND 31 469 764 or US$1916 per DALY averted).
Conversely, treatment of systolic blood pressure >160 mmHg is
the most cost-effective measure (VND 1 281 596 or US$78 per
DALY averted). With regard to the absolute risk approach, both
cost and cost-effectiveness ratios are disproportional to the
increase of the risk thresholds.
Figure 2 plots the total costs and effects of all single or
combined interventions based on point estimates. The solid
line, the expansion path, connects the most cost-effective
interventions which would be selected in order to achieve
greatest health gain given increasing levels of available
resources. The movement would start with individual treatment
of systolic blood pressure >160 mmHg (I2) at the budget level
of VND 264 billion per year (US$16.1 million) and then move
to individual treatment of systolic blood pressure >140 mmHg
(I1). If additional resources became available, combined treat-
ment for those who have an absolute risk of a CVD event in the
next 10 years of 25% (I7), 15% (I6) and 5% (I5) should be
purchased, respectively. Incremental and average cost-
effectiveness ratios for the best individual interventions are
shown in Figure 3.
Results of one-way sensitivity analysis and worst/best-case
scenario analysis are represented in Table 5. Without age
weights and discounting, average cost-effectiveness ratios
reduced more than a half, moving almost all interventions to
the very-cost effective category, except for individual treatment
of cholesterol >5.7 mmol. With lower estimates of effect sizes,
significant increases in average cost-effectiveness ratios of both
population and individual interventions to reduce cholesterol
were recorded. Notably, health education programme to reduce
smoking was very sensitive, moving from very cost-effective to
the cost-effective category (VND 12 324 059 per DALY versus
VND 29 574 642 per DALY averted). Higher effect sizes did not
have much effect on overall average cost-effectiveness ratios, in
the sense that they did not move interventions to reduce
cholesterol to the very cost-effective category. While no signifi-
cant changes were recorded when halving the base drug prices,
we found that when drug prices were doubled, individual
treatment to reduce cholesterol >5.7 is no longer cost-effective,
and combination drug treatment for absolute risk of CVD over
5% moves from very cost-effective to the cost-effective category.
Overall, the combination of lower health effects and double
drug prices (worst-case) made all interventions least cost-
effective. In the worst-case scenario, both individual treatments
of cholesterol above 5.7 and 6.2 mmol were not cost-effective
(VND 61 554 243 per DALY and VND 43 643 450 per DALY
averted, respectively), and media smoking campaign and
combination treatment for above 5% absolute risk moved
from very cost-effective to cost-effective. On the contrary, in
the best-case scenario, all interventions were very cost-effective,
except individual treatment of cholesterol >5.7 which still
remained in the cost-effective category. Results of sensitivity
analyses showed that individual treatment of systolic blood
pressure >160 mmHg is always the first choice based on point
estimates, and the most commonly chosen expansion path
(60%) is the combination of individual treatment of systolic
blood pressure >160 mmHg and combination treatment of
absolute risks of 25%, 15% and 5%, respectively.
Probabilistic, multivariate sensitivity analysis showed the range
of possible point estimates for the expansion path is very wide and
there are overlaps between uncertainty intervals (Figure 4). As a
result, there is much uncertainty about the choice of interven-
tions. An alternative solution is to use a stochastic league table
produced by MCLeague. Figure 5 summarizes the likelihood that a
single or combined intervention is selected to maximize health
gain at a given available level of budget, creating a stochastic
budget expansion path. At the budget level of less than VND 170
billion per year (US$10.4 million), a health programme to reduce
salt intake is chosen in a range of 40–70% probability of being
cost-effective. As resources available increase up to VND 250
billion per year (US$15.2 million), the mass media combination
programme is added with a probability ranging from 50–80%. The
coverage expands to individual treatment of systolic blood
pressure >160 mmHg as the budget increases over VND 270
billion per year.
Discussion
Results of this analysis demonstrate that all population-wide
interventions and the majority of individual measures focusing
on reducing risk factors of CVD are very cost-effective. Where
resources are scare (less than VND 250 billion per year), a
health education programme to reduce salt intake and a
combined mass media programme (on salt, tobacco and
cholesterol) are the most cost-effective measures and should
be purchased first. As more resources are made available,
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Figure 3 Incremental and average cost-effectiveness ratios for the
most cost-effective interventions. Notes: CER¼ cost-effectiveness ratio;
ICER¼ incremental cost-effectiveness ratio; ACER¼ average
cost-effectiveness ratio; DALY¼disability-adjusted life year;
SBP¼ systolic blood pressure.
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individual treatment of systolic blood pressure >160 mmHg and
combination treatment based on absolute risks of a cardiovas-
cular event of 25%, 15% and 5% in the next 10 years could then
be potentially implemented in Vietnam.
Our findings shared many, but not all, similarities with recent
cost-effectiveness analyses of interventions to reduce cardio-
vascular diseases. They are consistent with what were estimated
by Murray et al. (2003) for the Western Pacific Region B,
to which Vietnam belongs, except for interventions to re-
duce cholesterol (I3–I4). While Murray et al. found
cholesterol-lowering drug interventions are very cost-effective,
we found them merely cost-effective, even not cost-effective
when drug prices were doubled. Moreover, our average
cost-effectiveness estimates are significantly higher than the
regional estimates, due to higher costs and lower health
effectiveness. These divergences emphasize the importance of
using local and context-specific information to support national
priority-setting efforts. Finally, our interventions based on the
absolute risk approach using a multi-drug regimen had similar
cost-effective results to recent analyses conducted for and in
developing countries (Gaziano et al. 2006; Rubinstein et al.
2009).
Our application of WHO-CHOICE to Vietnam has several
caveats. First, although we made use of much local data on
costs and epidemiology, no national data on the epidemiology
of sodium consumption was available. In the absence of this
information, we therefore derived epidemiology and effect
estimates from other international studies and then worked
with the panel of experts to determine conservative estimates in
order to adjust to the context of Vietnam. Secondly, we did not
incorporate in the models other benefits, i.e. decrease in the
risk of gastric cancer due to reduced salt intake (Tsugane et al.
2004; Tsugane 2005), or resistance which may be caused by
platelet-active drugs (Patrono et al. 2004).
Importantly, this paper has several implications for the policy
debate on prevention and control of CVD in Vietnam. First, like
other developing countries, Vietnam faces serious financial
constraints. A recent report has revealed that, amongst other
things, the national budget for health care is unable to meet the
people’s health care needs, the effectiveness of utilization of the
state budget is still limited, and more importantly, resources
spent on preventive medicine are far from adequate (MOH
2008). As a result, spending the health budget wisely and
efficiently has become increasingly important. Our results
provide health policy-makers with more information on what
prevention strategies to reduce CVD are cost-effective and how
they should be purchased if additional resources are available,
thereby increasing efficiency in resource allocation. Specifically,
according to the request of the MOH (MOH 2007), the budget
allocated for CVD prevention and control was about VND 80
billion in 2008 (US$4.7 million). At this budget level, the mass
media campaign to increase population awareness of the risk
factors of CVD, such as salt intake and high cholesterol
concentration, should be the first choice. In the long run,
ideally cardiovascular health promotion should be a part of the
national media strategy. This suggestion was also recommended
for the South Asia countries, which, along with Vietnam, are
in the second stage of the epidemiologic transition (Nishtar
2002).T
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Secondly, as the budget allocated for the control and
prevention of CVD is projected to increase in the coming
years, it is recommended that health policy-makers expand the
individual prevention treatment of systolic blood pressure,
especially for those who have elevated levels over 160 mmHg
(which is the most cost-effectiveness intervention). While the
extensive development of pharmacies throughout the country
would make the scale-up of pharmaceutical interventions more
feasible and less costly, and the recent achievement in the
expansion of health insurance coverage through several special
programmes targeting poor and less affluent people was found
to increase access to health care (Ekman et al. 2008), there
remains some debate around screening for risk factors and
adherence to treatment. For example, for those who have high
systolic blood pressure, adherence to the life-long treatment
regime with two or more antihypertensive agents could be
affected by cultural preferences and beliefs (Betancourt et al.
1999), clinical inertia (O’Connor 2003), clinician-patient part-
nership (Barrier et al. 2003), and economic barriers (Bovet et al.
2002). Therefore, when implemented, these issues should not
be neglected. These same issues also apply to the administra-
tion of combination pharmacotherapy to those at an absolute
risk of experiencing a CVD event in the next 10 years,
particularly the latter economic constraint given the higher
per capita cost of implementation (e.g. US$1.13 per capita
population for the 25% risk level). This estimate is nearly
double that made in a recent modelling study of the financial
costs (and health effects) of scaling-up a multi-drug regimen in
developing countries, including Viet Nam (US$0.66 per capita
at 2005 price levels; Lim et al. 2007).
Thirdly, not only are the suggested prevention measures very
cost-effective, but they seem highly feasible in other aspects,
particularly from a financial perspective since estimated imple-
mentation costs are very low (less than a dollar per capita per
year for the most cost-effective strategies). Part of the reason
for this financial viability is that all drugs used for treating
hypertension and hyperlipidemia are now off-patent, available
widely across the country and can therefore be easily scaled up
through primary health care or outpatient clinics. Finally, an
education programme through mass media to reduce sodium
intake is highly recommended by WHO in the recent Forum
and Technical Meeting (WHO 2007). In Vietnam, such a
measure may prove to be even more effective because the
overall knowledge of risk factors for CVD among the
Vietnamese people remains relatively low.
Applying WHO-CHOICE using local and context-specific
information is a promising approach to improved evidence-
based health policy-making in developing countries where data
are limited and technical skills are scarce. The following are
some lessons learned from our application which other analysts
might find useful:
 first, a good panel of local experts representing multiple
disciplines plays an important role in guiding interventions
and providing insight into how to adjust WHO-CHOICE
information for the specific national context;
 second, it is important to fully understand how an
intervention pathway reflects the underlying biological
process of the disease question and the impact of the
intervention (i.e. from the developed intervention pathways,
ingredients used in the pathway are documented and then
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the amount of resources used in the intervention is
estimated);
 finally, conducting an economic evaluation using modelling
requires that appropriate evidence be elicited from multiple
and disparate sources (as opposed to cost-effectiveness
analysis undertaken alongside clinical trials). As a rule of
thumb, the evidence should not be identified selectively, but
derived from the best designed and least biased sources.
Conclusion
As cardiovascular diseases are escalating in Vietnam where
resources are very limited, there exists a constant tension over
how available resources can be used to best effect. Our analysis
brings fresh and practical evidence to policy debates on
prevention and control of cardiovascular diseases. Although
final decisions may be based on other grounds such as social
and geographical equity, cost-effectiveness is among the key
inputs and plays a unique role in how to allocate scare
resources. Using the results of this analysis would lead to policy
making in Vietnam being driven more by evidence, thereby
making decisions more explicit and systematic.
Acknowledgements
We would like to thank Vietnam Health Strategy and Policy
Institute, The School of Population Health at the University of
Queensland, Non-Communicable Disease Program, National
Heart Institute, Department of Health System and Financing,
WHO-Geneva, and WHO office in Hanoi for their support and
for sharing data.
This work was funded in part by a grant from the Vietnam
Education Foundation (VEF), Jiaikai Foundation, and the
Developing Evidence Base for Health Policy in Vietnam
(VINE) project funded by Atlantic Philanthropies.
Disclaimer
The views expressed in this paper are solely the responsibility of
the named authors and do not necessarily reflect the decisions
or stated policy of the organizations they work for.
References
Adam T, Evans DB, Murray CJ. 2003. Econometric estimation of
country-specific hospital costs. Cost Effectiveness and Resource
Allocation 1: 3.
Antithrombotic Trialists Collaboration. 2002. Collaborative meta-analysis
of randomised trials of antiplatelet therapy for prevention of death,
myocardial infarction, and stroke in high risk patients. British
Medical Journal 324: 71–86.
Asaria P, Chisholm D, Mathers C et al. 2007. Chronic disease prevention:
health effects and financial costs of strategies to reduce salt intake
and control tobacco use. The Lancet 370: 2044–53.
Barrier PA, Li JTC, Jensen NM. 2003. Two words to improve
physician-patient communication: what else? Mayo Clinic
Proceedings 78: 211–6.
Betancourt JR, Carrillo JE, Green AR. 1999. Hypertension in multicul-
tural and minority populations: linking communication to compli-
ance. Current Hypertension Reports 1: 482–8.
Treatment 
of SBP>160
Treatment 
of SBP>160
Treatment 
of SBP>160
Treatment 
of SBP>160
Treatment 
of SBP>160
Treatment 
of SBP>160
Treatment 
of SBP>160
Treatment 
of SBP>160
Media combination
Media combination
Media combination
Media combination
Media combination
Media salt campaign
Media salt campaign
Media salt campaign
Media salt campaign
20%
30%
40%
50%
60%
70%
80%
90%
100%
69 89 109 129 149 169 189 209 229 249 269 289 309 329 349 369 389 409 429 449 469 489
Budget per year (VND billions)
Pr
ob
ab
ili
ty
 o
f b
ei
ng
 c
os
t-e
ffe
ct
iv
e 
   
 
Figure 5 Stochastic budget expansion path Note: SBP¼ systolic blood pressure.
220 HEALTH POLICY AND PLANNING
Bovet P, Burnier M, Madeleine G et al. 2002. Monitoring one-year
compliance to antihypertension medication in the Seychelles.
Bulletin of the World Health Organization 80: 33–9.
Bradford RH, Shear CL, Chremos AN et al. 1991a. Expanded Clinical
Evaluation of Lovastatin (EXCEL) study results: I. Efficacy in
modifying plasma lipoproteins and adverse event profile in 8245
patients with moderate hypercholesterolemia. Archives of Internal
Medicine 151: 43–9.
Bradford RH, Shear CL, Chremos AN et al. 1991b. Expanded Clinical
Evaluation of Lovastatin (EXCEL) study results: III. Efficacy in
modifying lipoproteins and implications for managing patients
with moderate hypercholesterolemia. American Journal of Medicine
91: 18S–24S.
Collins R, MacMahon S. 1994. Blood pressure, antihypertensive drug
treatment and the risks of stroke and of coronary heart disease.
British Medical Bulletin 50: 272–98.
Collins R, Peto R, MacMahon S et al. 1990. Blood pressure, stroke and
coronary heart disease. Part 2: Short-term reductions in blood
pressure: overview of randomised drug trials in their epidemio-
logical context. The Lancet 335: 827–38.
Cuong TQ, Dibley MJ, Bowe S et al. 2007. Obesity in adults: an emerging
problem in urban areas of Ho Chi Minh City, Vietnam. European
Journal of Clinical Nutrition 61: 673–81.
Dahlof B, Sever PS, Poulter NR et al. 2005. Prevention of cardiovascular
events with an antihypertensive regimen of amlodipine adding
perindopril as required versus atenolol adding bendroflumethiazide
as required, in the Anglo-Scandinavian Cardiac Outcomes
Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre
randomised controlled trial. The Lancet 366: 895–906.
Drummond MF. 2005. Methods for the Economic Evaluation of Health Care
Programmes. Oxford: Oxford University Press.
Eastern Stroke and Coronary Heart Disease Collaborative Research
Group. 1998. Blood pressure, cholesterol, and stroke in eastern
Asia. The Lancet 352: 1801–7.
Edejer TTT, Baltussen R, Adam T et al. 2003. WHO Guide to
Cost-Effectiveness Analysis. Geneva: World Health Organization.
Ekman B, Liem NT, Duc HA et al. 2008. Health insurance reform in
Vietnam: a review of recent developments and future challenges.
Health Policy and Planning 23: 252–63.
Ezzati M. 2004. Comparative Quantification of Health Risks: Global and
Regional Burden of Disease Attributable to Selected Major Risk Factors.
Geneva: World Health Organization.
Farquhar JW, Fortmann SP, Flora JA et al. 1990. Effects of community-
wide education on cardiovascular disease risk factors. The Stanford
Five-City Project. The Journal of the American Medical Association 264:
359–65.
Flessa S, Dung NT. 2004. Costing of services of Vietnamese hospitals:
identifying costs in one central, two provincial and two district
hospitals using a standard methodology. International Journal of
Health Planning and Management 19: 63–77.
Forrester T, Adeyemo A, Soarres-Wynter S et al. 2004. A randomized
trial on sodium reduction in two developing countries. Journal of
Human Hypertension 19: 55–60.
Fortmann SP, Williams PT, Hulley SB et al. 1981. Effect of health
education on dietary behavior: the Stanford Three Community
Study. American Journal of Clinical Nutrition 34: 2030–8.
Friend K, Levy DT. 2002. Reductions in smoking prevalence and
cigarette consumption associated with mass-media campaigns.
Health Education Research 17: 85–98.
Gaziano TA, Opie LH, Weinstein MC. 2006. Cardiovascular disease
prevention with a multidrug regimen in the developing world: a
cost-effectiveness analysis. The Lancet 368: 679–86.
Gold MR, Siegel JE, Russell LB et al. 1996. Cost-Effectiveness in Health and
Medicine. New York: Oxford University Press.
Government of Vietnam. 2004. Resolution of the Government No. 204/
2004/NÐ-CP dated December 14, 2004 on salary scale of civil
servant. Hanoi: Government of Vietnam.
Gueyffier F, Boutitie F, Boissel JP et al. 1997. Effect of antihypertensive
drug treatment on cardiovascular outcomes in women and men: a
meta-analysis of individual patient data from randomized, con-
trolled trials. Annals of Internal Medicine 126: 761–7.
He FJ, MacGregor GA. 2002. Effect of modest salt reduction on blood
pressure: a meta-analysis of randomized trials. Implications for
public health. Journal of Human Hypertension 16: 761–70.
Hutton G, Baltussen R. 2005. Cost valuation in resource-poor settings.
Health Policy and Planning 20: 252–9.
Hutubessy R, Chisholm D, Edejer TT. 2003. Generalized
cost-effectiveness analysis for national-level priority-setting in the
health sector. Cost Effectiveness and Resource Allocation 1: 8.
Intersalt Cooperative Research Group. 1988. Intersalt: an international
study of electrolyte excretion and blood pressure. Results for
24 hour urinary sodium and potassium excretion. British Medical
Journal 297: 319–28.
Khai GP, Viet LN, Son TP et al. 2008. Epidemiological survey of
hypertension and its risk factors in Vietnam. Presentation at the
World Health Organization’s office, Hanoi, Vietnam.
Kottke TE, Gatewood LC, Wu SC et al. 1988. Preventing heart disease: is
treating the high risk sufficient? Journal of Clinical Epidemiology 41:
1083–93.
Lauer JA, Rohrich K, Wirth H et al. 2003. PopMod: a longitudinal
population model with two interacting disease states. Cost
Effectiveness and Resource Allocation 1: 6.
Law MR, Frost CD, Wald NJ. 1991. By how much does dietary salt
reduction lower blood pressure? III. Analysis of data from trials of
salt reduction. British Medical Journal 302: 819–24.
Levy DT, Bales S, Lam NT et al. 2006. The role of public policies in
reducing smoking and deaths caused by smoking in Vietnam:
results from the Vietnam tobacco policy simulation model. Social
Science & Medicine 62: 1819–30.
Lim SS, Gaziano TA, Gakidou E et al. 2007. Prevention of cardiovascular
disease in high-risk individuals in low-income and middle-income
countries: health effects and costs. The Lancet 370: 2054–62.
MacMahon S, Peto R, Cutler J et al. 1990. Blood pressure, stroke, and
coronary heart disease. Part 1, Prolonged differences in blood
pressure: prospective observational studies corrected for the
regression dilution bias. The Lancet 335: 765–74.
MacMahon S, Rodgers A. 1993. The effects of antihypertensive treat-
ment on vascular disease: reappraisal of the evidence in (1994).
Journal of Vascular Medicine and Biology 4: 265–5.
MOH. 2003. Report on results of the Vietnam National Health Survey
2001–2002. Hanoi: Ministry of Health and General Statistics Office
of Vietnam.
MOH. 2007. Prevention of Hypertension Project for the period 2008–2010.
Hanoi: Ministry of Health of Vietnam.
MOH. 2008. Joint Annual Health Review 2008: Health Financing in Viet Nam.
Hanoi: Ministry of Health of Vietnam.
MSH. 2007. International Drug Price Indicator Guide. Boston, MA:
Management Sciences for Health.
Murray CJ, Evans DB, Acharya A et al. 2000. Development of WHO
guidelines on generalized cost-effectiveness analysis. Health
Economics 9: 235–51.
Murray CJL, Lauer JA, Hutubessy RCW et al. 2003. Effectiveness and
costs of interventions to lower systolic blood pressure and
COST-EFFECTIVENESS ANALYSIS OF CVD IN VIETNAM 221
cholesterol: a global and regional analysis on reduction of
cardiovascular-disease risk. The Lancet 361: 717–25.
Neal B, MacMahon S, Chapman N. 2000. Effects of ACE inhibitors,
calcium antagonists, and other blood-pressure-lowering drugs:
results of prospectively designed overviews of randomised trials.
Blood Pressure Lowering Treatment Trialists’ Collaboration. The
Lancet 356: 1955–64.
Nishtar S. 2002. Prevention of coronary heart disease in south Asia. The
Lancet 360: 1015–8.
O’Connor PJ. 2003. Overcome clinical inertia to control systolic blood
pressure. Archives of Internal Medicine 163: 2677–8.
Patrono C, Coller B, FitzGerald GA et al. 2004. Platelet-active drugs: the
relationships among dose, effectiveness, and side effects: the
Seventh ACCP Conference on Antithrombotic and Thrombolytic
Therapy. The American College of Chest Physicians 126: 234–64.
Prospective Studies Collaboration. 1995. Cholesterol, diastolic blood
pressure, and stroke: 13,000 strokes in 450,000 people in 45
prospective cohorts. The Lancet 346: 1647–53.
Puska P, Salonen JT, Nissinen A et al. 1983. Change in risk factors for
coronary heart disease during 10 years of a community interven-
tion programme (North Karelia project). British Medical Journal
(Clinical Research Edition) 287: 1840–4.
Rose G, Khaw KT, Marmot M. 2008. Rose’s Strategy of Preventive Medicine:
The Complete Original Text. New York: Oxford University Press.
Rubinstein A, Martı´ SG, Souto A et al. 2009. Generalized cost-
effectiveness analysis of a package of interventions to reduce
cardiovascular disease in Buenos Aires, Argentina. Cost Effectiveness
and Resource Allocation 7: 10.
Stein EA, Lazkarzewski P, Steiner P. 1993. Lovastatin 5-year safety and
efficacy study. Archives of Internal Medicine 153: 1079–87.
Tian HG, Guo ZY, Hu G et al. 1995. Changes in sodium intake and blood
pressure in a community-based intervention project in China.
Journal of Human Hypertension 9: 959–68.
Tikkanen MJ, Helve E, Ja¨a¨ttela¨ A et al. 1988. Comparison between
lovastatin and gemfibrozil in the treatment of primary hyperchol-
esterolemia: the Finnish Multicenter Study. The American Journal of
Cardiology 62: 35J–43J.
Tsugane S. 2005. Salt, salted food intake, and risk of gastric cancer:
epidemiologic evidence. Cancer Science 96: 1–6.
Tsugane S, Sasazuki S, Kobayashi M et al. 2004. Salt and salted food
intake and subsequent risk of gastric cancer among middle-aged
Japanese men and women. British Journal of Cancer 90: 128–34.
Tuan NT, Tuong PD, Popkin BM. 2008. Body mass index (BMI)
dynamics in Vietnam. European Journal of Clinical Nutrition 62:
78–86.
UN-EU. 2007. UN–EU Guidelines for Financing of Local Costs in
Development Co-operation with Vietnam. UN Agencies, the
Embassies of the EU Member States, and the EC Delegation to
Vietnam.
WHO. 2001. Macroeconomics and Health: Investing in Health for Economic
Development. Geneva: World Health Organization.
WHO. 2002. The World Health Report 2002: Reducing Risks, Promoting
Healthy Life. Geneva: World Health Organization.
WHO. 2007. Reducing Salt Intake in Populations: Report of a WHO Forum and
Technical Meeting. Geneva: World Health Organization.
Williams B. 2006. Evolution of hypertensive disease: a revolution in
guidelines. The Lancet 368: 6–8.
222 HEALTH POLICY AND PLANNING
